High definition Lasofoxifene - Acotiamide Hydrochloride Trihydrate CAS 773092-05-0 API Manufacturer High Purity – Ruifu

Manufacturer with High Purity and Stable Quality Chemical Name: Acotiamide Hydrochloride Trihydrate CAS: 773092-05-0 In the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. API High Quality, Commercial Production

Chemical Name	Acotiamide Hydrochloride Trihydrate
Synonyms	YM-443, Z-338
CAS Number	773092-05-0
CAT Number	RF-API34
Stock Status	In Stock, Production Scale Up to Hundreds of Kilograms
Molecular Formula	C21H31ClN4O5S
Molecular Weight	487.013
Brand	Ruifu Chemical

Item	Specifications
Appearance	White or Off-White Powder
Purity / Analysis Method	≥98.0% (HPLC)
Residual Solvent Ethanol	≤0.50%
Moisture (K.F)	9.0%～12.0%
Individual Impurity	≤0.50%
Total Impurities	≤1.0%
Residue on Ignition	≤0.20%
1H NMR	Corresponds to the Structure
Test Standard	Enterprise Standard
Usage	Active Pharmaceutical Ingredient (API)

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation. Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of Acotiamide Hydrochloride Trihydrate (CAS: 773092-05-0) with high quality. Acotiamide, also known as YM-443 and Z-338, is a drug approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. It acts as an acetylcholinesterase inhibitor. Note: The Approved drug API is a cotiamide HCl trihydrate (1:1:3). Acotiamide Hydrochloride is the hydrochloride salt form of acotiamide, a prokinetic agent with gastrointestinal (GI) motility-enhancing activity. It is a new orally active selective acetylcholinesterase inhibitor. Acotiamide monohydrochloride trihydrate enhances acetylcholine released by enteric neurons through muscarinic receptor antagonism and acetylcholinesterase (AChE) inhibition, thereby enhancing gastric emptying and gastric accommodation.